Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-007286

CHIEF FINANCIAL OFFICER acquired 10,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2025-03-04 Option exercise +10,000 $2.48 $24,800 23,000 D: show line 1 in the form

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2025-03-04 Option exercise · Stock Option (right to buy) −10,000 132,806 D: show line 2 in the form
Loading xslF345X05/form4-03062025_110331.xml…